Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.

Morris C, Iacobelli S, Gahrton G, van Biezen A, Drake M, Garderet L, Potter M, Schattenberg AV, Cornelissen JJ, Hamladji RM, Martelli M, Petersen E, Rovira M, Bandini G, Kroger N, de Witte T.

Biol Blood Marrow Transplant. 2015 Jun;21(6):1054-8. doi: 10.1016/j.bbmt.2015.02.012. Epub 2015 Feb 20.

2.
3.

Efficacy and outcome of autologous transplantation in rare myelomas.

Morris C, Drake M, Apperley J, Iacobelli S, van Biezen A, Bjorkstrand B, Goldschmidt H, Harousseau JL, Morgan G, de Witte T, Niederwieser D, Gahrton G; Myeloma Subcommittee of Chronic Leukaemia Working Party of EBMT.

Haematologica. 2010 Dec;95(12):2126-33. doi: 10.3324/haematol.2010.022848. Epub 2010 Oct 22.

4.

Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.

Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, Fisher D, Gribben J, Freeman A, Parikh B, Richardson P, Soiffer R, Ritz J, Anderson KC.

Bone Marrow Transplant. 2003 Dec;32(12):1145-51. Review.

PMID:
14647268
5.

Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry.

Passera R, Pollichieni S, Brunello L, Patriarca F, Bonifazi F, Montefusco V, Falda M, Montanari M, Guidi S, Giaccone L, Mordini N, Carella AM, Bavaro P, Milone G, Benedetti F, Ciceri F, Scimè R, Benedetti E, Castagna L, Festuccia M, Rambaldi A, Bacigalupo A, Corradini P, Bosi A, Boccadoro M, Bandini G, Fanin R, Bruno B.

Biol Blood Marrow Transplant. 2013 Jun;19(6):940-8. doi: 10.1016/j.bbmt.2013.03.012. Epub 2013 Mar 26.

6.

The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.

Patriarca F, Carobolante F, Zamagni E, Montefusco V, Bruno B, Englaro E, Nanni C, Geatti O, Isola M, Sperotto A, Buttignol S, Stocchi R, Corradini P, Cavo M, Fanin R.

Biol Blood Marrow Transplant. 2015 Jun;21(6):1068-73. doi: 10.1016/j.bbmt.2015.03.001. Epub 2015 Mar 6.

7.

Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Kawamura K, Takamatsu H, Ikeda T, Komatsu T, Aotsuka N, Amano I, Yamamoto G, Watanabe K, Ohno Y, Matsue K, Kouzai Y, Tsukada N, Ishiyama K, Anzai N, Kato K, Suzuki R, Sunami K, Kanda Y.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1291-8. doi: 10.1016/j.bbmt.2015.02.015. Epub 2015 Feb 21.

8.

IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.

Wechalekar A, Amato D, Chen C, Keith Stewart A, Reece D.

Ann Hematol. 2005 Feb;84(2):115-7. Epub 2004 Oct 22.

PMID:
15503021
9.

Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma.

Osman K, Elliott B, Mandeli J, Scigliano E, Malone A, Isola L, Grosskreutz C.

Am J Hematol. 2010 Apr;85(4):249-54. doi: 10.1002/ajh.21633.

10.

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, Juliusson G, Ahlberg L, Nagler A, Shimoni A, Sureda A, Boiron JM, Einsele H, Chopra R, Carella A, Cavenagh J, Gratwohl A, Garban F, Zander A, Björkstrand B, Niederwieser D, Gahrton G, Apperley JF; Chromic Leukaemia Working Party of the EBMT.

Blood. 2005 Jun 1;105(11):4532-9. Epub 2005 Feb 24.

11.

Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study.

Reece DE, Vesole DH, Shrestha S, Zhang MJ, Pérez WS, Dispenzieri A, Milone GA, Abidi M, Atkins H, Bashey A, Bredeson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, Kumar S, Kyle RA, Lazarus HM, McCarthy PL, Pavlovsky S, Roy V, Weisdorf DJ, Wiernik PH, Hari PN.

Clin Lymphoma Myeloma Leuk. 2010 Dec;10(6):458-63. doi: 10.3816/CLML.2010.n.078.

12.

Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.

Huff CA, Fuchs EJ, Noga SJ, O'Donnell PV, Ambinder RF, Diehl L, Borrello I, Vogelsang GB, Miller CB, Flinn IA, Brodsky RA, Marcellus D, Jones RJ.

Biol Blood Marrow Transplant. 2003 May;9(5):312-9.

13.

Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.

Peggs KS, Mackinnon S, Williams CD, D'Sa S, Thuraisundaram D, Kyriakou C, Morris EC, Hale G, Waldmann H, Linch DC, Goldstone AH, Yong K.

Biol Blood Marrow Transplant. 2003 Apr;9(4):257-65.

14.

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.

Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2039-2051. doi: 10.1016/j.bbmt.2015.09.016. Epub 2015 Sep 30.

15.

Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.

Peterlin P, Delaunay J, Guillaume T, Gastinne T, Mahé B, Dubruille V, Blin N, Le Bourgeois A, Brissot E, Lodé L, Le Gouill S, Moreau P, Mohty M, Chevallier P.

Biol Blood Marrow Transplant. 2015 Jan;21(1):180-4. doi: 10.1016/j.bbmt.2014.08.018. Epub 2014 Aug 28.

16.

Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma.

Arora M, McGlave PB, Burns LJ, Miller JS, Barke JN, Defor TE, Weisdorf DJ.

Bone Marrow Transplant. 2005 Jun;35(12):1133-40.

PMID:
15834435
17.

Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.

Stella-Holowiecka B, Czerw T, Holowiecka-Goral A, Giebel S, Wojnar J, Holowiecki J.

Transplant Proc. 2007 Nov;39(9):2893-7.

PMID:
18022010
18.

Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.

Patriarca F, Einsele H, Spina F, Bruno B, Isola M, Nozzoli C, Nozza A, Sperotto A, Morabito F, Stuhler G, Festuccia M, Bosi A, Fanin R, Corradini P.

Biol Blood Marrow Transplant. 2012 Apr;18(4):617-26. doi: 10.1016/j.bbmt.2011.07.026. Epub 2011 Aug 3.

19.

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.

Kröger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas JF, Schwerdtfeger R, Kiehl M, Fauser A, Sayer HG, Leon A, Beyer J, Zabelina T, Ayuk F, San Miguel JF, Brand R, Zander AR.

Biol Blood Marrow Transplant. 2004 Oct;10(10):698-708.

20.

Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.

Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G.

J Clin Oncol. 2011 Aug 1;29(22):3016-22. doi: 10.1200/JCO.2010.32.7312. Epub 2011 Jul 5. Erratum in: J Clin Oncol. 2011 Sep 20;29(27):3721.

PMID:
21730266

Supplemental Content

Support Center